Phaos Technology Holdings (Cayman) (POAS) Common Equity (2024 - 2025)
Phaos Technology Holdings (Cayman) (POAS) reported Common Equity of -$1.5 million for Q2 2025, down 167.72% on a YoY basis from $2.2 million in Q2 2024, and down 167.72% quarter-over-quarter from $2.2 million in Q2 2024.
Phaos Technology Holdings (Cayman) (POAS) Common Equity (2024 - 2025) Analysis & Trends
Phaos Technology Holdings (Cayman) has reported Common Equity for 2 years, with the latest figure at -$1.5 million in Q2 2025.
- For the quarter ending Q2 2025, Common Equity fell 167.72% year-over-year to -$1.5 million; the trailing twelve-month figure through Apr 2025 stood at -$1.5 million (down 167.72% YoY), and the FY2025 full-year result was -$1.5 million, down 169.34% from the prior year.
- Common Equity for Q2 2025 stood at -$1.5 million, down from $2.2 million in the prior quarter.
- The five-year high for Common Equity was $2.2 million in Q2 2024, with the low at -$1.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 52.70 Bn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 22.98 Bn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 48.99 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 26.10 Bn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 10.33 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 2.96 Bn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 10.68 Bn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 7.20 Bn |
| 10 | Phaos Technology Holdings (Cayman) | 682,234.12 | 627,245.12 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2025 | -1.47 Mn |
| Apr 30, 2024 | 2.17 Mn |